Expert Consultations: Real-World Answers

Perinatal Treatment of Bipolar Disorder – Interview

Published on July 1, 2024 Certification expiration date: July 1, 2027

Guest

Radwa Hanafy

To unlock this audio you need to become a Silver, Gold, Silver extended, Gold extended, Gold – fr, Gold extended – fr, Silver – fr or Silver extended – fr Member.

Check Our CME Program

Downloads for Offline Access

Download Audio File (MP3)

Interview Highlights

Lithium toxicity should be prevented by maintaining good hydration, avoiding low-sodium diets, and refraining from using medication such as NSAIDs.
Pregnancy may require higher doses of lamotrigine. Adjustments to the dosage should be considered in the early weeks after childbirth.

Text Version

This edition of the Psychopharmacology Institute’s Expert Consultations features Vivien Burt, M.D., Ph.D, professor of psychiatry at the University of California, Los Angeles. Dr. Burt is a Consulting Director and Founder of the Women's Life Center at the UCLA Neuropsychiatric Hospital. In this interview, we will discuss the perinatal treatment of bipolar disorder.

Dr. Hanafy: Welcome to the Psychopharmacology Institute! You are listening to Expert Consultations, and I'm your host, Dr. Radwa Hanafy. Our topic for today is the

Unlock this Expert Consultation and earn 0.50 CMEs
Become a Silver, Gold, Silver extended, Gold extended, Gold – fr, Gold extended – fr, Silver – fr or Silver extended – fr Member.

Get Instant Access

Already have an account? Sign in

Learning Objectives:

After completing this activity, the learner will be able to:

Explain the concept of "satisficing" in treating pregnant women with bipolar disorder.
Evaluate the risks and benefits of continuing lithium therapy during pregnancy.
Distinguish the fetal risks of mood stabilizers like valproate, carbamazepine, and lamotrigine during pregnancy.
Outline the role of antipsychotic medication in treating bipolar disorder during pregnancy and its associated congenital risks.

Released Date: July 1, 2024
Expiration Date: July 1, 2027

Expert: Vivien Burt, M.D.
Medical Editors: Radwa Hanafy, M.D., Lorena Rodriguez, M.D.

Relevant Financial Disclosures:

None of the faculty, planners, and reviewers for this educational activity have relevant financial relationships to disclose during the last 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Contact Information: For questions regarding the content or access to this activity, contact us at support@ml-prod.psychopharmacologyinstitute.com

Instructions for Participation and Credit:

Participants must complete the activity online during the valid credit period that is noted above.

Follow these steps to earn CME credit:

View the required educational content provided on this course page.
Complete the Post Activity Evaluation for providing the necessary feedback for continuing accreditation purposes and for the development of future activities. NOTE: Completing the Post Activity Evaluation after the quiz is required to receive the earned credits.
Download your certificate.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

Medical Academy designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Vivien K. Burt, M.D., Ph.D.